

ASX ANNOUNCEMENT

29 May 2024

Results of Annual General Meeting

SYDNEY, 29 May 2024: Anteris Technologies Ltd (ASX: AVR) is pleased to announce the following results from the Annual General Meeting held on 29 May 2024.

At today's Annual General Meeting all Resolutions put to Shareholders were passed by a Poll.

Details of the Proxy and Poll Votes are attached.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

REGISTERED OFFICE

Toowong Tower, Level 3, Suite 302
9 Sherwood Road
Toowong, QLD 4066
Australia



BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

T: +61 1300 550 310
info.au@anteristech.com
anteristech.com

Authorisation and Additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
Twitter	@AnterisTech
Facebook	www.facebook.com/AnterisTechnologies
LinkedIn	https://www.linkedin.com/company/anteristech



The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of the Remuneration Report	Ordinary	4,843,918 96.65%	161,016 3.21%	7,378 0.14%	51,402	5,745,112 97.27%	161,016 2.73%	53,573	Carried
2 Re-election of Wenyi Gu as Director	Ordinary	4,905,474 97.15%	136,392 2.70%	7,553 0.15%	50,487	5,420,169 91.17%	525,237 8.83%	50,487	Carried
4 Ratification and approval of prior issue of Shares on 2 November and 16 November 2023 under Listing Rule 7.1	Ordinary	4,812,978 98.91%	45,820 0.94%	7,378 0.15%	49,261	5,297,417 99.10%	47,991 0.90%	56,561	Carried
5 Ratification and approval of prior issue of Shares on 17 April 2024 under Listing Rule 7.1	Ordinary	4,812,919 98.91%	45,820 0.94%	7,437 0.15%	49,261	5,354,017 99.11%	47,991 0.89%	56,561	Carried
6(a) Approval of grant of Options to Wayne Paterson	Ordinary	1,914,871 89.47%	217,895 10.18%	7,378 0.35%	2,792,886	2,597,166 85.75%	431,665 14.25%	2,800,186	Carried
6(b) Approval of grant of Options to John Seaberg	Ordinary	1,914,871 89.47%	217,895 10.18%	7,378 0.35%	2,792,886	2,595,516 85.74%	431,665 14.26%	2,792,886	Carried
6(c) Approval of grant of Options to Stephen Denaro	Ordinary	1,936,236 90.47%	196,495 9.18%	7,413 0.35%	2,792,886	2,229,721 73.62%	799,110 26.38%	2,800,186	Carried
6(d) Approval of grant of Options to Wenyi Gu	Ordinary	1,936,446 90.48%	196,320 9.17%	7,378 0.35%	2,792,886	2,229,896 73.62%	798,935 26.38%	2,800,186	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

Resolution	Instructions given to validly appointed proxies
3 Approval of 10% Placement Facility	Resolution was not put to the meeting as shareholder approval of additional placement capacity under ASX Listing Rule 7.1A is no longer available to the Company.